AXID CAPSULE

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

NIZATIDINE

Inapatikana kutoka:

PENDOPHARM DIVISION OF PHARMASCIENCE INC

ATC kanuni:

A02BA04

INN (Jina la Kimataifa):

NIZATIDINE

Kipimo:

300MG

Dawa fomu:

CAPSULE

Tungo:

NIZATIDINE 300MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100

Dawa ya aina:

Prescription

Eneo la matibabu:

HISTAMINE H2-ANTAGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0120317002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2002-02-04

Tabia za bidhaa

_ _
_AXID (nizatidine) _
_Page 1 of 27_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AXID®
Nizatidine Capsules
Capsules 150 mg, 300 mg, Oral
USP
Histamine H
2
Receptor Antagonist
PENDOPHARM, Division of Pharmascience Inc.
6111 Royalmount Avenue, Suite 100
Montréal, QC, Canada
H4P 2T4
Date of Revision:
July 20, 2021
Submission Control Number: 247715
® Registered trademark of Pharmascience Inc.
_ _
_ _
_AXID (nizatidine) _
_Page 2 of 27_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................4
4.2
Recommended Dose and Dosage
Adjustment.......................................................4
4.4
Administration.....................................................................................................5
4.5
Missed Dose
........................................................................................................5
5
OVERDOSAGE
...............................................................................................................5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
...................................6
7
WARNINGS AND PRECAUTIONS
...................................